Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in Hypermutated mCRPC
NCT02966587Phase 2Withdrawn
- Sponsor
- University of Washington
- Start
- May 2018
- Primary completion
- May 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Washington. Primary endpoint: Response rate to durvalumab up to 3 years. Planned start May 2018; status: withdrawn.
02
Drugs
durvalumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02966587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966587.